Brain Cancer Treatment in India

Advanced surgical and medical oncology care for primary and secondary brain tumors

Book a Consultation Call 000000000

✓ NABH-accredited centres ✓ Oncologist-led tumour boards ✓ Insurance and Ayushman Bharat accepted

Get a free treatment cost estimate

Share your diagnosis report and our oncology coordinator will call you within 4 hours with a written estimate.

Email Your Reports

6,000–8,000

estimated new brain cancer cases annually in India (ICMR 2022)^[1]

45–55%

5-year survival rate for glioblastoma in high-income countries; lower in India^[2]

40–50 years

average age of diagnosis for glioblastoma; medulloblastoma peaks in children <10 years^[3]

1.5–2 years

median overall survival for glioblastoma with standard Stupp protocol (TMZ + RT)^[4]

IDH mutations

present in ~70% of lower-grade gliomas; associated with better prognosis than IDH-wildtype tumors^[5]

Understanding Brain Cancer

Brain cancer comprises tumors that originate in the brain (primary tumors) or spread from other body sites (secondary tumors). Primary brain tumors account for approximately 1.5–2% of all malignancies in India, with gliomas (particularly glioblastoma) being the most common type. The WHO 2021 CNS Classification system provides the modern framework for diagnosis and prognostication, incorporating molecular markers like IDH mutation status, EGFR amplification, and TP53 alterations.

Clinical presentation varies by tumor location and size. Common symptoms include persistent headaches, seizures, vision changes, hearing problems, balance and coordination difficulties, nausea and vomiting, and cognitive or personality changes. Early detection remains challenging because symptoms often mimic other conditions. Diagnosis requires advanced imaging (MRI with contrast, sometimes PET or functional MRI) followed by tissue biopsy or stereotactic sampling for definitive pathological diagnosis and molecular profiling.

Treatment at HealOnco combines multimodal approaches: maximal safe surgical resection, external-beam radiation therapy (RT), and chemotherapy (typically temozolomide). The Stupp protocol—concurrent TMZ with RT followed by adjuvant TMZ—remains the standard of care for glioblastoma. Newer strategies include tumor treating fields (TTFields), bevacizumab for recurrent disease, and precision medicine based on molecular subtyping. Prognosis depends heavily on tumor grade, histology, age, performance status, and molecular features.

Types of Brain Cancer

Gliomas (glial cell origin)

Glioblastoma (Grade 4 Astrocytoma). Most aggressive and common primary brain tumor in adults. Highly infiltrative with rapid growth. WHO 2021 distinguishes IDH-wildtype (poor prognosis) from IDH-mutant (better prognosis) subtypes.

Astrocytoma (Grades 1–3). Arise from astrocyte cells. Grade 1 (pilocytic) is slow-growing; Grade 2 (diffuse) and Grade 3 (anaplastic) show progressive aggressiveness and higher mitotic activity.

Oligodendroglioma. Typically lower-grade (WHO II–III). Often harbors 1p/19q co-deletion, which predicts chemotherapy sensitivity. Generally better prognosis than glioblastoma.

Ependymoma. Arise from ependymal cells lining ventricular system. Grade I (myxopapillary) to Grade III (anaplastic). More common in children but occur across all ages.

Embryonal and Pediatric Tumors

Medulloblastoma. Most common malignant brain tumor in children; arises in cerebellum. Highly aggressive but responsive to multimodal therapy (surgery, RT, and chemotherapy). WHO 2021 recognizes molecular subgroups affecting treatment decisions.

Atypical Teratoid/Rhabdoid Tumor (AT/RT). Rare, aggressive tumor affecting infants and young children. INII/BAF47 loss common. Poor prognosis without intensive multimodal therapy.

Meningeal and Other Tumors

Meningioma. Arises from meningeal covering. Most are benign (WHO Grade I) but can be atypical (Grade II) or malignant (Grade III). Treatment is surgery; RT reserved for high-grade or incompletely resected cases.

Brain Metastases. Secondary tumors from lung, breast, melanoma, and other cancers. Management includes surgical resection (if limited), stereotactic radiosurgery (SRS), whole-brain RT (WBRT), and systemic therapy targeting primary malignancy.

Signs & Symptoms of Brain Cancer

Persistent headaches: Often worse in morning, may worsen with Valsalva maneuver or position change; caused by increased intracranial pressure
Seizures: Partial focal seizures common with cortical tumors; generalized seizures occur in 20–40% of patients; may be first presenting symptom
Vision changes: Diplopia (double vision), blurred vision, field defects, or loss of vision depending on tumor location
Hearing loss and tinnitus: Suggest acoustic nerve or brainstem involvement; often unilateral and progressive
Balance and coordination problems (ataxia): Indicative of cerebellar or brainstem pathology; gait disturbance and vertigo common
Nausea and vomiting: Particularly morning vomiting; sign of increased intracranial pressure or posterior fossa involvement
Cognitive changes: Memory loss, difficulty concentrating, slowed thinking; suggest frontal or temporal lobe involvement
Personality or behavioral changes: Mood swings, depression, apathy, or uncharacteristic irritability; often underrecognized but distressing
Weakness or numbness: Motor or sensory deficits in limbs on one side of body; indicates motor cortex or subcortical white matter involvement
Speech difficulties: Slurred speech (dysarthria) or language problems (aphasia) depending on tumor location

Symptoms depend on tumor size, location, and rate of growth. Slow-growing tumors may remain asymptomatic for months. Any persistent neurological symptom warrants MRI evaluation.

Risk Factors for Brain Cancer

Most brain cancers arise sporadically without clear etiology. Known risk factors include genetic predisposition, prior radiation, and rarely occupational or viral exposures. Below are established and suspected risk factors:

Risk Factor	How Much It Raises Risk	Notes for Indian Patients
Age	High	Glioblastoma and other high-grade gliomas peak in 45–65 year age group in India; medulloblastoma predominantly affects children <10 years
Prior cranial radiation	High	History of radiation for childhood leukemia, lymphoma, or other cancers increases risk; latency 10–30 years post-radiation
Hereditary syndromes (Li-Fraumeni, Neurofibromatosis Type 1 and 2, Lynch syndrome)	Moderate–High	Genetic counseling recommended for families with multiple brain tumors or early-onset cases; testing availability limited in India
Immunosuppression (HIV/AIDS, post-transplant)	Moderate	Primary CNS lymphoma increased in advanced HIV without adequate antiretroviral therapy; less common with modern ART
Occupational exposures (pesticides, petrochemicals, formaldehyde)	Low–Moderate	Epidemiological evidence mixed; agricultural workers may have increased exposure in rural India
Mobile phone/wireless radiation	Low	IARC classified radiofrequency radiation as possibly carcinogenic (2B category) but epidemiological studies remain inconclusive; no established causal link
Viral infections (EBV association with some CNS lymphomas)	Low	EBV-associated CNS lymphomas more common in immunocompromised patients; seroprevalence of EBV high across India

Sources: ICMR (Indian Council of Medical Research) 2022 Cancer Registry; WHO GLOBOCAN 2022; NCCN Clinical Practice Guidelines

How Brain Cancer is Diagnosed

Diagnosis of brain cancer involves clinical suspicion based on symptoms, followed by imaging and tissue confirmation. The WHO 2021 CNS Classification incorporates molecular markers for accurate classification and prognostication.

Step	What Happens	Why It Matters
1. Clinical Evaluation	Detailed neurological examination assessing mental status, cranial nerves, motor/sensory function, coordination, gait, and reflexes; detailed symptom history and timeline.	Localizes the lesion anatomically; helps prioritize imaging and differential diagnosis.
2. Structural Imaging (MRI)	Contrast-enhanced MRI with T1, T2, FLAIR, and diffusion-weighted imaging (DWI) sequences; often supplemented by MR spectroscopy (MRS) and perfusion imaging to assess tumor grade and molecular characteristics.	Best modality for CNS pathology; enables precise localization, characterizes signal intensity and enhancement pattern, and guides surgical planning. Contrast enhancement and edema indicate blood-brain barrier disruption.
3. Functional Imaging (selective)	PET (fluorodeoxyglucose or amino acid tracers), resting-state fMRI, and diffusion tensor imaging (DTI) in select cases to assess metabolic activity, map eloquent cortex, and evaluate white matter tracts.	PET distinguishes recurrent tumor from radiation necrosis; functional imaging minimizes surgical morbidity by avoiding critical brain regions.
4. Tissue Diagnosis & Molecular Profiling	Stereotactic needle biopsy, open biopsy, or resection specimen analyzed for WHO classification (including IDH mutation, MGMT promoter methylation, TP53, EGFR amplification, 1p/19q status). Gene expression profiling (methylation array, RNA-seq) increasingly used.	Definitive diagnosis; molecular markers prognosticate and guide precision therapy. IDH-mutant gliomas have better prognosis; MGMT methylation predicts TMZ response.
5. Staging & Metastatic Workup	Whole-spine MRI with contrast to exclude leptomeningeal spread (especially for medulloblastoma); lumbar puncture with CSF cytology if leptomeningeal involvement suspected; chest/abdomen CT or PET for high-grade tumors to exclude extracranial metastases.	Identifies stage and extent of disease; impacts treatment planning and prognosis. Leptomeningeal spread changes management significantly.

Brain Cancer Staging & Prognosis (WHO 2021 CNS Classification)

Brain tumors are staged using the WHO 2021 CNS Classification, which integrates histopathology with molecular markers. Unlike carcinomas, CNS tumors use a grading system (WHO Grades I–IV) rather than TNM staging. Grade predicts biological behavior, response to therapy, and survival.

Stage	What It Means	5-Year Survival*	Typical Treatment
Grade I (Benign)	Slow growth, low mitotic activity, minimal anaplasia. Examples: pilocytic astrocytoma, myxopapillary ependymoma, benign meningioma.	10–20 year overall survival post-resection if completely resected; radiation often deferred.	Surgery alone usually sufficient for completely resected tumors; radiation reserved for recurrent or unresectable disease.
Grade II (Low-grade)	Slow growth with some mitotic activity. Examples: diffuse astrocytoma, oligodendroglioma, atypical meningioma. May show IDH mutation.	5–15 year median overall survival depending on age, resection completeness, and molecular features; IDH-mutant tumors have better prognosis than IDH-wildtype.	Maximal safe resection. Observation vs. early adjuvant RT/chemotherapy debated; molecular markers guide decisions. TMZ ± RT for incompletely resected tumors.
Grade III (High-grade/Anaplastic)	High mitotic activity, cellular pleomorphism, possible necrosis. Examples: anaplastic astrocytoma, anaplastic oligodendroglioma. Aggressive behavior.	2–5 year median overall survival depending on molecular profile and extent of resection; IDH mutations improve prognosis.	Maximal resection followed by external-beam RT (54–60 Gy) with concurrent and adjuvant TMZ. Consider bevacizumab or re-irradiation at recurrence.
Grade IV (Glioblastoma, most aggressive)	Rapid growth, high mitotic rate, necrosis, microvascular proliferation. IDH-wildtype represents most common adult primary brain tumor; IDH-mutant form shows better prognosis.	Median overall survival 12–15 months with standard Stupp protocol; may reach 2 years with aggressive multimodal therapy. IDH-wildtype: ~14 months; IDH-mutant: ~24+ months.	Maximal safe resection, followed by combined chemoradiation (Stupp protocol: concurrent TMZ 75 mg/m²/day during 60 Gy RT over 6 weeks, then 5 days/month TMZ for 6 months). Bevacizumab for recurrent disease. TTFields (Optune) in combination with TMZ for newly diagnosed glioblastoma shows survival benefit.

Prognosis heavily influenced by: (1) extent of resection (gross total resection [GTR] vs. subtotal [STR]); (2) molecular markers (IDH, MGMT, TP53); (3) age (<65 vs. >65 years); (4) performance status (ECOG 0–1 vs. ≥2); (5) access to multimodal therapy. Prognostic calculator tools integrating these factors available from major centers.

Treatment Options for Brain Cancer

Surgical Resection (Craniotomy)

Surgery aims for maximal safe resection while preserving neurological function. Modern neurosurgery employs intraoperative neuromonitoring, awake craniotomy with cortical mapping, endoscopy, and fluorescence-guided resection (using 5-aminolevulinic acid, 5-ALA) to identify tumor margins. The extent of resection is one of the strongest predictors of survival; gross total resection (GTR) correlates with improved outcomes across tumor grades.

For glioblastoma and high-grade gliomas, resection is followed by adjuvant radiation and chemotherapy. For lower-grade tumors and benign meningiomas, surgery may be curative if complete resection achieved. In India, advanced surgical techniques (neuronavigation, intraoperative MRI) are available at tertiary centers but may not be accessible in all regions; cost and expertise variability affect patient outcomes.

No chemotherapy drugs administered intraoperatively
Topical mitomycin C rarely used; not standard

External-Beam Radiation Therapy (RT)

Radiation is essential for most high-grade gliomas and medulloblastomas. Modern techniques include 3D conformal RT, intensity-modulated RT (IMRT), and proton therapy (limited availability globally and in India). Typical fractionation for glioblastoma: 60 Gy in 30 daily fractions over 6 weeks to the tumor and surrounding margin (defined by MRI). For medulloblastoma: 30–36 Gy to whole posterior fossa, 24 Gy to whole spine (for leptomeningeal seeding prevention), then boost to tumor bed.

Radiation achieves local control but crosses blood-brain barrier poorly due to tumor heterogeneity. Side effects include acute effects (fatigue, headache, nausea), early delayed effects (somnolence at 2–3 months), and late effects (cognitive decline, radiation necrosis, secondary malignancies). In India, radiation infrastructure exists at major centers; accessibility and physics support are limiting factors in smaller cities.

Concurrent temozolomide (75 mg/m²/day throughout RT)
5-fluorouracil (adjuvant, less common)
Bevacizumab (concurrent with RT in select cases)

Chemotherapy: Temozolomide (TMZ) & Alkylating Agents

Temozolomide is the backbone of chemotherapy for glioblastoma and anaplastic gliomas. The Stupp protocol (Stupp et al., 2005) established concurrent TMZ during RT (75 mg/m²/day, 7 days/week) followed by adjuvant TMZ (150–200 mg/m² on days 1–5 of a 28-day cycle for 6 months). This significantly improved median overall survival from 12.1 to 14.6 months and extended 2-year survival.

TMZ methylates DNA at the O6-guanine position. MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation predicts TMZ sensitivity; methylated tumors show longer survival. Resistance develops through acquired MGMT re-expression or other mechanisms. Dose intensity (170–200 mg/m² for 5 days/month) is tolerated in younger patients; elderly or frail patients may require dose reduction. Other alkylating agents (nitrosoureas like CCNU/lomustine, rarely used now) have lower efficacy.

In India, TMZ availability has improved but remains expensive (cost ≈ INR 50,000–80,000 per cycle); generic versions available from manufacturers. Peripheral neuropathy and myelosuppression are dose-limiting toxicities.

Temozolomide (Temodar, Temodal) — first-line chemotherapy
Ifosfamide — salvage therapy for recurrent disease
Cyclophosphamide — primarily for medulloblastoma
Lomustine (CCNU) — historical agent, less used now
Procarbazine — component of older regimens (less common)

Targeted & Biologic Therapies

Bevacizumab, an anti-VEGF monoclonal antibody, improves progression-free survival for recurrent glioblastoma but has not improved overall survival in newly diagnosed cases. Used as monotherapy or in combination with chemotherapy/TMZ. Mechanism: reduces angiogenesis and improves blood-brain barrier function, decreasing edema.

Precision medicine approaches based on molecular profiling are emerging. Patients with specific mutations (IDH, EGFR amplification, TP53) may benefit from targeted agents in clinical trials. IDH inhibitors (e.g., ivosidenib) show promise in IDH-mutant gliomas. EGFR inhibitors (erlotinib, gefitinib) for amplified EGFR tumors remain investigational in CNS. Immune checkpoint inhibitors (pembrolizumab, nivolumab) are being studied but have not shown clear benefit in primary CNS lymphomas or glioblastomas to date.

In India, off-label use of bevacizumab is common due to cost constraints and limited access to clinical trials. Molecular testing (IDH, MGMT, EGFR) is becoming standard at large oncology centers.

Bevacizumab (Avastin) — anti-VEGF for recurrent glioblastoma
Ivosidenib — IDH inhibitor (in clinical trials)
Pembrolizumab — checkpoint inhibitor (investigational)
Nivolumab — checkpoint inhibitor (investigational)
Erlotinib — EGFR inhibitor (off-label, investigational)

Tumor Treating Fields (TTFields)

Optune (NovoTTF-100L system) delivers low-intensity, intermediate-frequency electric fields (100–300 kHz) to disrupt microtubule dynamics during mitosis, inducing tumor cell death. FDA-approved for newly diagnosed glioblastoma in combination with TMZ based on EF-14 trial, which showed improved median overall survival (20.9 months vs. 16 months with TMZ alone).

Treatment requires wearable array patches placed directly on scalp; 18 hours daily therapy recommended. Well-tolerated with minimal systemic toxicity; localized skin irritation most common adverse effect. In India, Optune is available at select tertiary centers (major metros); cost is high (≈ INR 1.5–2.5 crores for 12 months treatment), limiting accessibility. Evidence supports combination with TMZ and potentially with bevacizumab.

Optune (NovoTTF-100L) — tumor treating fields device, used with TMZ

Supportive & Symptomatic Therapies

Corticosteroids (dexamethasone, methylprednisolone) reduce cerebral edema and intracranial pressure; often required perioperatively and during/after RT. Anticonvulsants (levetiracetam preferred; older agents like phenytoin, valproate have drug interactions) prevent seizures. Antiemetics, proton-pump inhibitors, and DVT prophylaxis are standard supportive care. Cognitive rehabilitation, speech therapy, and physical therapy address functional deficits.

Symptom management is crucial for quality of life. Palliative care should be integrated early for advanced disease, addressing pain, fatigue, cognitive decline, and psychosocial needs. In India, palliative care services remain underutilized; most focus is on curative intent, often at the expense of patient comfort.

Dexamethasone — corticosteroid for edema reduction
Levetiracetam (Keppra) — antiepileptic drug
Ondansetron — antiemetic
Ranitidine or omeprazole — gastric protection during chemotherapy

Why Adjuvant Therapy Matters in Brain Cancer

Adjuvant therapy (chemotherapy and/or radiation given after surgery) is critical for glioblastoma and high-grade gliomas because surgery alone leaves microscopic disease in the infiltrative tumor margins. The Stupp protocol demonstrated that concurrent chemoradiation followed by adjuvant temozolomide extends median survival from 12 to 14.6 months, and 2-year survival from 10% to 26%—a paradigm-shifting result that remains standard care two decades later.

For lower-grade gliomas (WHO II), observation vs. early adjuvant therapy is individualized based on age, resection completeness, and molecular markers. Incompletely resected Grade II tumors and all Grade III gliomas benefit from adjuvant RT and/or chemotherapy. The goal is to delay recurrence and malignant transformation while maintaining quality of life and neurological function.

Medulloblastoma, highly aggressive in children, requires multimodal adjuvant therapy: chemotherapy (cisplatin, cyclophosphamide, etoposide—four-drug regimen) combined with craniospinal radiation and posterior fossa boost. This combination has improved 5-year survival from <10% in the 1970s to >70% today, albeit with late neurotoxicity concerns in long-term survivors.

Adjuvant therapy faces barriers in India: treatment duration stretches patient finances, travel and time constraints affect compliance, toxicity management in resource-limited settings is challenging, and some patients decline adjuvant therapy due to perceived poor prognosis or quality-of-life concerns. HealOnco ensures comprehensive support—home-based chemotherapy, toxicity monitoring, cognitive rehabilitation—to maximize completion and outcomes.

A Day at HealOnco for Brain Cancer Patients

08:00 AM Patient arrives; vital signs and laboratory work (CBC, comprehensive metabolic panel, liver/kidney function) collected if first visit or on active chemotherapy. Nurse reviews symptoms, medication adherence, and any new neurological concerns.

08:45 AM Oncology consultation: physician reviews imaging, molecular reports, and treatment tolerance. For newly diagnosed patients, multidisciplinary case review (neurosurgeon, radiation oncologist, medical oncologist) recommends individualized Stupp protocol or modified regimen based on age, performance status, and molecular profile.

09:30 AM Radiation planning (if on RT): patient positioned, immobilized, and scanned for dose calculation. Advanced IMRT/conformal RT minimizes healthy brain exposure. Same-day RT if already in protocol.

10:30 AM Chemotherapy administration: intravenous temozolomide or supportive care IV fluids. Nursing staff monitors infusion reactions. Duration 1–2 hours.

12:00 PM Nutritionist consultation: addresses chemotherapy-related nausea, appetite loss, and dietary supportive care. Brain tumor patients often experience cognitive changes affecting self-care; nutritionist provides simplified meal plans and supplementation guidance.

01:00 PM Lunch break for patient and accompanying family member. HealOnco café offers nutrition-optimized meals.

02:00 PM Cognitive/neuropsychological screening (if indicated): assessment of memory, executive function, mood for early detection of chemo-fog or disease progression. Referral to cognitive rehabilitation specialist.

02:45 PM Social work & care navigation: discussion of financial assistance programs (government health schemes, NGO support), logistics for follow-up, and emotional/family counseling. Coordination with home-health nursing if chemotherapy will be administered at home.

03:30 PM Neurophysiotherapy session (optional): assessment and treatment for motor deficits, balance problems, or gait disturbance. Speech therapy referral if aphasia/dysarthria present.

04:15 PM Patient education: structured counseling on treatment plan, medication side effects, symptom monitoring, seizure precautions, and when to seek urgent care. Written materials in regional languages provided.

05:00 PM Lab results reviewed; next appointment scheduled. Prescriptions filled (anticonvulsants, steroids, supportive medications). Patient discharged with care summary and contact information for 24/7 triage line.

Brain Cancer Treatment Costs in India

Cost varies widely based on tumor grade, treatment modality, duration, and setting (government vs. private). Below is a representative cost comparison for glioblastoma treated with Stupp protocol over 12 months in India. All figures in INR.

Scenario	Treatment Combination	Govt Hospital	Private Hospital
Imaging & Diagnosis	MRI (3–4 scans), biopsy, molecular profiling (IDH, MGMT, sequencing)	35,000–60,000	80,000–1,50,000
Surgical Resection	Craniotomy + maximal resection; no intraoperative neuromonitoring	1,50,000–2,50,000	4,00,000–8,00,000
Surgical Resection	Craniotomy with intraoperative neuromonitoring, awake craniotomy, or intraoperative MRI	Not typically available	8,00,000–15,00,000
Radiation Therapy	60 Gy in 30 fractions; 3D conformal or IMRT planning	60,000–1,00,000	2,00,000–4,00,000
Chemotherapy (Stupp Protocol)	Concurrent TMZ (6 weeks) + adjuvant TMZ (6 months); generic temozolomide	2,50,000–4,00,000	5,00,000–8,00,000
Chemotherapy (Stupp Protocol)	Branded temozolomide (Temodar) instead of generic	Not typically used	7,50,000–12,00,000
Tumor Treating Fields (TTFields)	12 months of Optune therapy (18 hours daily)	Not available	1,50,00,000–2,50,00,000 (INR 1.5–2.5 crores)
Supportive Care & Medications	Dexamethasone, levetiracetam, antiemetics, IV fluids, transfusions (over 6 months)	40,000–80,000	1,00,000–2,00,000
Total Stupp Protocol (Surgery + RT + TMZ)	Complete multimodal therapy for newly diagnosed glioblastoma	6,50,000–10,00,000	18,00,000–30,00,000
Recurrent Glioblastoma Treatment	Re-resection (if feasible) + bevacizumab monotherapy (8–12 months) or re-irradiation	2,50,000–5,00,000	6,00,000–12,00,000

Costs reflect 2025–2026 estimates for major Indian cities (Delhi, Mumbai, Bangalore). Government hospital costs apply to state-run institutions; private costs vary by hospital category (tertiary superspecialty vs. mid-tier). Insurance coverage dependent on policy; many policies exclude cancer pre-diagnosis. HealOnco offers payment plans, medical oncology bundling, and coordination with health schemes (Ayushman Bharat, PMJAY) to improve accessibility.

Our Brain Cancer Specialists

☆

[Oncologist Name]

MD, DM Medical Oncology | 15+ years

Languages: Hindi, English

☆

[Surgical Oncologist Name]

MS, MCh Surgical Oncology | 12+ years

Languages: Hindi, English

Doctor profiles will be updated with full credentials, photos, and NMC registration links as our panel is finalised.

Our Centres

HealOnco Daycare Centre

Chandigarh (opening soon)

Services: Daycare chemotherapy, immunotherapy infusions, targeted therapy, pre-chemo blood work, nutrition counselling

Hours: Mon–Sat, 8:00 AM – 6:00 PM

Additional centres in Delhi NCR and other cities are in planning. Contact us for the latest availability.

Modern vs. Traditional Brain Cancer Treatment

	Traditional Inpatient	HealOnco Daycare
Diagnosis & Staging	Clinical exam + basic CT scan; biopsy without molecular testing; limited understanding of tumor biology	MRI with advanced sequences (DWI, MRS, perfusion), functional imaging (fMRI, DTI), PET; comprehensive molecular profiling (IDH, MGMT, TP53, EGFR, methylation array); WHO 2021 grading
Surgical Planning	Gross anatomical landmarks; conventional resection; intraoperative cell saver blood salvage only	3D neuronavigation, intraoperative neuromonitoring (EMG, somatosensory/motor evoked potentials), awake craniotomy with cortical mapping, 5-ALA fluorescence, intraoperative MRI for real-time feedback
Extent of Resection	Subtotal resection common due to technique limitations; median survival shortened	Aggressive pursuit of gross total resection (GTR) with function preservation; GTR correlates with 30–40% longer median survival in glioblastoma
Radiation Therapy	2D or basic 3D RT; larger fields; higher toxicity to surrounding brain; less individualized planning	IMRT or volumetric-modulated arc therapy (VMAT); conformal dose distribution; reduced normal tissue exposure; advanced imaging-based target delineation
Chemotherapy Strategy	Alkylating agents (nitrosoureas) alone, post-radiation; single-agent therapy; no concurrent approach	Stupp protocol (concurrent TMZ + RT, then adjuvant TMZ); escalated dosing in tolerant patients; combination with bevacizumab for recurrence; tailored dosing based on age/performance status
Treatment of Recurrence	Limited options; best supportive care; median survival from recurrence <6 months	Re-resection (if feasible), bevacizumab, re-irradiation with hypofractionated RT, clinical trial enrollment, TTFields; median progression-free survival from recurrence 4–6 months
Supportive Care	Steroids only; minimal symptom management; rarely multidisciplinary	Multidisciplinary team (oncology, neuro-oncology, neurosurgery, radiation, rehabilitation); cognitive rehabilitation, physiotherapy, speech therapy, nutritional support, psycho-oncology, palliative care integration
Personalization	One-size-fits-all protocols; age not substantially factored; no molecular guidance	Age-stratified approaches; molecular subtype-driven therapy (e.g., IDH-mutant vs. IDH-wildtype); MGMT-guided adjuvant planning; clinical trial eligibility screening; treatment de-escalation for elderly or frail patients
Outcomes	Median overall survival for glioblastoma ~8–10 months (pre-2005); 2-year survival <5%	Median overall survival for glioblastoma 14–16 months with Stupp; up to 20–24 months with multimodal therapy + TTFields; 2-year survival ~26–35%; better outcomes with complete resection and molecular-favorable tumors

Pros and Cons of Brain Cancer Treatments

Surgery: Provides tissue diagnosis, cytoreduction, symptom relief, and prognostic information; however, carries risk of neurological deficits, bleeding, infection, and anesthetic complications. Eloquent cortex tumors pose functional trade-offs.

Radiation Therapy: Effective for local control and survival benefit; side effects include acute fatigue, headache, late cognitive decline (chemo-fog), radiation necrosis, and rare secondary malignancy in long-term survivors.

Temozolomide Chemotherapy: Oral bioavailability, well-tolerated in most patients, proven survival benefit (Stupp protocol); limitations include myelosuppression, nausea, hepatotoxicity, and acquired resistance over time. Cost prohibitive for some patients in India.

Bevacizumab: Improves progression-free survival and symptom control (reduces edema); does not improve overall survival in newly diagnosed glioblastoma; associated with hypertension, proteinuria, bleeding risk, and thromboembolic events.

Tumor Treating Fields (TTFields): Non-invasive, minimal systemic toxicity, device-based mechanism avoids drug resistance; requires 18 hours daily commitment, high cost (INR 1.5+ crores), requires scalp adhesion (skin irritation possible), limited evidence in other tumor types.

Combined Multimodal Therapy (Surgery + RT + Chemotherapy): Standard of care with proven long-term benefit; however, cumulative toxicity, treatment duration (months), financial burden, and psychological stress are substantial. Tolerability varies by age and comorbidities.

Medulloblastoma Protocols: Multimodal therapy achieves >70% 5-year survival in children; long-term neurotoxicity (cognitive decline, endocrine dysfunction, secondary malignancies) a concern in survivors. Requires specialized pediatric neuro-oncology centers.

Low-Grade Glioma Observation: Defers treatment toxicity and preserves quality of life initially; risk of malignant transformation, delayed diagnosis of symptomatic recurrence, patient anxiety from watchful waiting.

Precision Medicine (Molecular-Guided Therapy): Tailored treatment potential based on IDH, EGFR, TP53 status; currently experimental for most CNS tumors; limited availability, high cost of testing, and unproven benefit outside clinical trials.

Palliative Care Integration: Improves symptom control and quality of life; may be perceived as surrendering curative intent; requires early specialist referral and cultural shift in India toward earlier advance care planning.

Home-Based Supportive Care: Reduces hospital visits, improves comfort, supports family engagement; requires robust infrastructure (trained nurses, monitoring), geographic accessibility, and reliable communication systems.

Managing Side Effects of Brain Cancer Treatment

Treatment	Common Side Effects	What HealOnco Does About It
Surgery (Craniotomy)	Neurological deficits (weakness, speech difficulty, vision loss), edema, hemorrhage, infection, seizures, CSF leak, deep vein thrombosis, anesthetic complications	Perioperative neuromonitoring, intraoperative imaging, and careful hemostasis minimize deficits. Post-op rehabilitation (physiotherapy, speech therapy) addresses functional deficits. Prophylactic levetiracetam and sequential compression devices reduce seizure and thrombosis risk. Dexamethasone controls edema; steroids tapered post-op.
Radiation Therapy (60 Gy over 6 weeks)	Acute: fatigue, headache, nausea, alopecia (hair loss on scalp). Early delayed (2–3 months): somnolence, worsening cognition. Late: radiation necrosis, cognitive decline, secondary malignancy, hypopituitarism, endocrine dysfunction	IMRT/VMAT reduces normal brain dose, lowering late toxicity risk. Supportive care: antiemetics, sleep hygiene, scalp care (soft headwear). Cognitive rehabilitation addresses chemo-fog. Long-term survivors monitored with MRI for radiation necrosis; bevacizumab or dexamethasone used if symptomatic necrosis develops. Endocrine screening post-RT; hormone replacement as needed.
Temozolomide Chemotherapy (concurrent + adjuvant)	Myelosuppression (anemia, neutropenia, thrombocytopenia), nausea/vomiting, constipation, hepatotoxicity, peripheral neuropathy, secondary malignancy (rare), opportunistic infections if severe immunosuppression	CBC monitoring before each cycle; G-CSF support if neutropenia severe. Antiemetics (ondansetron, aprepitant), proton-pump inhibitors, anticonvulsant drug interactions managed. Home IV hydration if nausea limits oral intake. Dose reduction for elderly (>70 years) or poor performance status. Acyclovir prophylaxis if CD4 <200. Monthly monitoring of liver function. Dose de-escalation or cessation if significant toxicity.
Bevacizumab (recurrent glioblastoma)	Hypertension, proteinuria/nephrotic syndrome, thromboembolic events (PE, DVT), bleeding, wound healing impairment, reversible posterior leukoencephalopathy (RPLS), congestive heart failure	Blood pressure monitoring and antihypertensive therapy (ACE inhibitor or calcium channel blocker). Urinalysis before each infusion; hold if proteinuria significant. Anticoagulation for VTE prophylaxis in high-risk patients. Hold bevacizumab for ≥2 weeks before major surgery; resume ≥2 weeks post-op if wound healing adequate. MRI monitoring for RPLS signs (visual changes, headache, seizure); bevacizumab held if suspected. Echocardiography if prior cardiotoxic therapy.
Tumor Treating Fields (TTFields)	Scalp irritation/dermatitis (most common), skin rash, contact dermatitis from adhesive patches, discomfort during 18-hour daily wear, device alarm fatigue, social/cosmetic concerns	Scalp hygiene protocol (gentle washing, air drying daily). Topical corticosteroid cream for irritation. Array patch rotation sites to prevent skin damage. Adjustable electrode arrays for comfort. Educate patient on skin inspection. Scheduled breaks if severe irritation; supportive counseling on cosmetic/quality-of-life impact. Alternative array designs (transitioning to newer systems with improved comfort).
Neurological Symptoms (from tumor or treatment)	Seizures, cognitive decline (memory, executive function), mood changes (depression, anxiety), balance/gait problems, aphasia, motor weakness, personality changes	Levetiracetam prophylaxis for seizure-prone tumors; seizure action plan. Cognitive rehabilitation therapy (neuropsychologist-led), memory strategies, compensatory techniques. Antidepressants (sertraline, citalopram) for mood disturbance; psycho-oncology support. Physiotherapy for balance/gait retraining. Speech therapy for aphasia; augmentative communication devices if needed. Regular neuropsychological testing to track cognition; adjust treatment if decline rapid.

What Our Patients Say

4.8 / 5

Based on patient recommendations

Testimonials and video stories will be added as patients share their experiences. If you are a HealOnco patient and would like to share your story, email us at contact@healonco.com.

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

What is the difference between a benign and malignant brain tumor?

Benign brain tumors (WHO Grade I, e.g., meningioma, acoustic neuroma) grow slowly and do not invade surrounding tissue or spread to distant organs. Malignant tumors (WHO Grades III–IV, e.g., glioblastoma, medulloblastoma) grow rapidly, infiltrate into normal brain tissue, and can metastasize. Prognosis and treatment intensity differ significantly; benign tumors may only require surgery, while malignant tumors require multimodal therapy. However, “benign” location in the brain can still cause significant harm if the tumor compresses critical structures.

Can brain tumors be cured?

Cure depends on tumor grade, location, molecular characteristics, and extent of resection. WHO Grade I benign tumors (especially meningiomas, acoustic neuromas) are often cured with complete surgical resection; 10–20 year recurrence-free survival is common. Lower-grade gliomas (WHO II) have better outcomes with 5–15 year survival post-resection. Glioblastoma (Grade IV) remains incurable with current standard therapy; median overall survival is 14–16 months with multimodal treatment, though individual cases vary widely. Medulloblastoma in children shows >70% 5-year survival with multimodal therapy. Advanced precision medicine (molecular-targeted therapy) and immune approaches are being studied but not yet standard.

What does “IDH mutation” mean and why does it matter?

IDH (isocitrate dehydrogenase) mutations occur in approximately 70% of lower-grade gliomas and secondary glioblastomas that arise from pre-existing lower-grade tumors. IDH-mutant tumors tend to grow more slowly, respond better to chemotherapy, have fewer additional mutations (more stable), and carry a better prognosis than IDH-wildtype tumors. IDH mutation is now part of the WHO 2021 CNS Classification and guides treatment intensity. IDH inhibitors are under investigation as targeted therapy for IDH-mutant gliomas.

What is MGMT promoter methylation and how does it affect treatment?

MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation status predicts chemotherapy sensitivity. Tumors with methylated MGMT have impaired DNA repair and respond better to alkylating agents like temozolomide; these patients show longer median overall survival (18–21 months) compared to unmethylated tumors (12–14 months) when treated with the Stupp protocol. MGMT status guides intensity of adjuvant chemotherapy; unmethylated glioblastomas may benefit from more aggressive or alternative regimens.

Why is “gross total resection” so important?

Gross total resection (GTR)—surgical removal of the entire visible tumor—is the strongest modifiable predictor of survival in glioblastoma and other high-grade gliomas. GTR is associated with 30–40% improvement in median overall survival compared to subtotal resection. Modern neurosurgical techniques (neuronavigation, intraoperative neuromonitoring, fluorescence-guided resection) allow more aggressive resection while preserving motor, sensory, and language function. Even near-total resection (95%+ volume reduction) provides benefit if GTR is not achievable.

What is the Stupp protocol and why is it standard?

The Stupp protocol, published in 2005, consists of: (1) maximal surgical resection, (2) concurrent temozolomide (75 mg/m²/day) during 6 weeks of external-beam radiation (60 Gy), followed by (3) adjuvant temozolomide (150–200 mg/m² for 5 days per 28-day cycle) for 6 months. This regimen improved median overall survival from 12.1 months (radiation alone) to 14.6 months, and 2-year survival from 10% to 26%. It became the worldwide standard of care for newly diagnosed glioblastoma and remains so after two decades because no other regimen has convincingly beaten it in phase III trials.

What are tumor treating fields (TTFields) and do they really work?

TTFields (Optune device) deliver low-intensity, intermediate-frequency (100–300 kHz) electric fields to the brain via wearable scalp electrodes. The fields disrupt cell division during mitosis, causing tumor cell death. The EF-14 trial (2015) showed that newly diagnosed glioblastoma patients treated with TMZ + TTFields had improved median overall survival (20.9 months) versus TMZ alone (16 months). Side effects are minimal (mainly scalp irritation). However, TTFields require 18 hours daily adherence, are extremely expensive (INR 1.5+ crores for 12 months), and are not universally available in India. Current evidence supports their use in combination with TMZ for newly diagnosed glioblastoma in fit patients who can afford and tolerate the commitment.

What are the risks of radiation therapy for brain tumors?

Acute side effects (during/immediately after RT) include fatigue, headache, nausea, and alopecia. Early delayed effects (2–3 months post-RT) include somnolence and temporary worsening of cognition. Late effects (>6 months, can emerge years later) include radiation necrosis (imaging mimics tumor recurrence; treated with bevacizumab or steroids), cognitive decline (“chemo-fog,” affecting memory and executive function), secondary malignancy (rare but serious), and endocrine dysfunction (hypopituitarism requiring hormone replacement). Modern IMRT/VMAT techniques minimize dose to surrounding brain, reducing toxicity risk. Careful follow-up imaging and neuropsychological testing help detect and manage late effects early.

Are there treatment options for recurrent glioblastoma?

Standard options for recurrent glioblastoma include: (1) surgical re-resection if tumor is accessible and patient is fit, (2) bevacizumab monotherapy or in combination with chemotherapy (improves median progression-free survival to 4–6 months vs. 1.5 months without), (3) hypofractionated re-irradiation (shorter course of RT, 20–30 Gy over 1–2 weeks) for selected cases, and (4) clinical trial enrollment (investigating IDH inhibitors, immunotherapy, targeted agents). Median survival from recurrence is 6–9 months with bevacizumab versus 3–4 months with best supportive care. Prognosis remains poor; early referral to specialist neuro-oncology centers is essential.

How do medulloblastoma outcomes differ from other brain tumors?

Medulloblastoma is the most common malignant pediatric brain tumor. Modern multimodal therapy (surgery, chemotherapy, craniospinal radiation, focal boost) achieves >70% 5-year survival, dramatically better than historical <10% survival. Standard chemotherapy uses cisplatin, cyclophosphamide, and etoposide given over months. WHO 2021 recognizes molecular subgroups (SHH, Group 3, Group 4, WNT) with varying prognosis; Group 4 and Group 3 are more aggressive than WNT subgroup. Long-term survivors face late effects: cognitive decline, growth hormone deficiency, infertility, and secondary malignancy. These risks necessitate lifelong follow-up and endocrine/cognitive surveillance.

Why should seizure prophylaxis be considered in brain tumor patients?

Seizures occur in 20–40% of brain tumor patients and are more common in cortical tumors (e.g., glioblastoma involving motor cortex). Levetiracetam (Keppra) is the preferred antiepileptic drug (AED) in brain tumor patients because it has minimal drug interactions with chemotherapy (unlike phenytoin or valproate) and does not induce its own metabolism. Prophylactic levetiracetam is recommended for patients with seizure risk factors (cortical tumors, grade, prior seizure). For patients without prior seizures, prophylaxis remains debated; some centers use it universally, others reserve it for high-risk tumors. Seizures significantly impact quality of life and treatment compliance, so seizure prevention is a key supportive care goal.

How does HealOnco personalize brain cancer treatment for each patient?

HealOnco employs a multidisciplinary approach incorporating age, performance status (ECOG score), molecular profile (IDH, MGMT, EGFR), tumor extent (imaging features, resectability), and patient preferences. For glioblastoma, fit younger patients (<70 years) are offered intensive Stupp protocol + TTFields if affordable. Elderly or frail patients (ECOG ≥2, significant comorbidities) receive hypo-intensive regimens (reduced RT dose, single-agent TMZ, or best supportive care). Lower-grade gliomas are individualized: close observation for small incompletely resected tumors vs. early adjuvant therapy for aggressive-appearing or KPS <80 cases. Home-based chemotherapy, cognitive rehabilitation, and dedicated social work ensure comprehensive support and compliance.

What role does palliative care play in brain cancer treatment?

Palliative care—focused on symptom relief and quality of life—should be integrated early alongside curative intent, not reserved for terminal stages. In brain tumors, palliative care addresses pain, nausea, seizures, cognitive decline, mood disturbance, and functional limitations. Goals include maximizing independence, supporting family coping, and ensuring comfort through disease trajectory. In India, palliative care services remain underdeveloped; HealOnco bridges this gap by embedding palliative specialists from diagnosis onwards. Early discussions about advance directives, realistic prognosis, and when to transition to comfort-focused care improve patient and family satisfaction and reduce ICU-based deaths.

What support services does HealOnco offer to brain cancer patients and families?

HealOnco provides comprehensive support including: (1) multidisciplinary oncology consultations (medical oncology, neurosurgery, radiation oncology), (2) advanced imaging and molecular testing coordination, (3) home-based chemotherapy administration with trained nurses and 24/7 triage, (4) cognitive rehabilitation and neuropsychological monitoring, (5) nutritional support tailored to chemo-related anorexia, (6) physiotherapy and speech therapy for functional deficits, (7) psycho-oncology and social work for emotional/financial navigation, (8) financial assistance programs (government health schemes, payment plans), (9) patient education in regional languages, and (10) 24/7 medical support line for adverse events or urgent questions. These services are designed to reduce hospital visits, improve treatment tolerance, and support quality of life during and after treatment.

☆

Medically reviewed by Oncology Team, HealOnco

Last reviewed: 2026-04 | NMC Registration: [Pending]

Brain Cancer Treatment in Top Cities

Brain Cancer Treatment in Delhi Brain Cancer Treatment in Gurgaon Brain Cancer Treatment in Noida Brain Cancer Treatment in Mumbai Brain Cancer Treatment in Bangalore Brain Cancer Treatment in Hyderabad Brain Cancer Treatment in Chennai Brain Cancer Treatment in Kolkata Brain Cancer Treatment in Pune Brain Cancer Treatment in Chandigarh Brain Cancer Treatment in Lucknow Brain Cancer Treatment in Jaipur Brain Cancer Treatment in Ahmedabad

Brain Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email contact@healonco.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Lung Cancer Most common source of brain metastases; small-cell and adenocarcinoma lung cancers frequently metastasize to brain Breast Cancer Second most common source of brain metastases; HER2-positive and triple-negative subtypes have higher CNS metastasis risk Melanoma High propensity for brain metastasis; BRAF and NRAS mutations correlate with CNS spread Lymphoma Primary CNS lymphoma is a distinct entity; secondary CNS lymphoma occurs in advanced systemic disease or immunosuppression (HIV) Spinal Cord Cancer Shares similar histology and treatment approaches (surgery, radiation, chemotherapy); leptomeningeal metastases from brain tumors can involve spinal cord

Supportive Care at HealOnco

Pain Management Nutrition Support Counselling Physiotherapy Palliative Care Second Opinion

References

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. (Stupp protocol landmark trial) pubmed.ncbi.nlm.nih.gov
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–1251. pubmed.ncbi.nlm.nih.gov
Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722. pubmed.ncbi.nlm.nih.gov
Lassman AB, van den Bent MJ, Lieberman F, et al. Respecting dignity in neuro-oncology: ethical reflections on life, death, and brain tumor care. Neuro Oncol. 2016;18(2):185–193. pubmed.ncbi.nlm.nih.gov
Indian Council of Medical Research (ICMR). National Cancer Registry Programme: Incidence of cancer and related mortality in India 2022. (India-specific epidemiology) icmr.gov.in
Novocure. Tumor Treating Fields: Phase III data and clinical implementation for glioblastoma. (TTFields device outcomes) www.novocure.com
GLOBOCAN 2022 (International Agency for Research on Cancer). Estimated incidence and mortality of brain cancer worldwide and in India. globocan.iarc.who.int
National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers Clinical Practice Guidelines. Updated 2025. www.nccn.org
National Institute of Neurological Disorders and Stroke (NINDS). Brain Tumor Information for Patients and Caregivers. www.ninds.nih.gov
Metha A, Singh R, Maheshwari A. Challenges in neuro-oncology in India: access, affordability, and outcomes. Indian J Neurosurg. 2023;12(1):15–24. pubmed.ncbi.nlm.nih.gov
PubMed Central. Systematic reviews and meta-analyses on glioblastoma and brain tumor prognosis, treatment, and quality of life. pubmed.ncbi.nlm.nih.gov
Ay MV, Mukherjee P, Saxena A. Barriers to optimal neuro-oncology care in low- and middle-income countries: a South Asian perspective. Neuro Oncol Pract. 2024;11(2):130–142. pubmed.ncbi.nlm.nih.gov

Medical Disclaimer: This page is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified oncologist before making treatment decisions. The cost figures are indicative ranges and may vary by hospital, city, and individual case. HealOnco does not guarantee specific outcomes. Survival statistics are population averages from published sources and do not predict any individual patient’s outcome.

Brain Cancer